WO2007095353A3 - Gpcrs as angiogenesis targets - Google Patents
Gpcrs as angiogenesis targets Download PDFInfo
- Publication number
- WO2007095353A3 WO2007095353A3 PCT/US2007/004114 US2007004114W WO2007095353A3 WO 2007095353 A3 WO2007095353 A3 WO 2007095353A3 US 2007004114 W US2007004114 W US 2007004114W WO 2007095353 A3 WO2007095353 A3 WO 2007095353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiogenesis
- provides methods
- gpcrs
- lec3
- ednra
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 4
- 102100036793 Adhesion G protein-coupled receptor L3 Human genes 0.000 abstract 3
- 101710096347 Adhesion G protein-coupled receptor L3 Proteins 0.000 abstract 3
- 102000017914 EDNRA Human genes 0.000 abstract 3
- 101000967336 Homo sapiens Endothelin-1 receptor Proteins 0.000 abstract 2
- 108050006947 CXC Chemokine Proteins 0.000 abstract 1
- 102000019388 CXC chemokine Human genes 0.000 abstract 1
- 108010090549 Endothelin A Receptor Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides methods of modulating angiogenesis by increasing or decreasing expression or function of G-Protein Coupled Receptors (GPCRs) namely Lectomedin-3 (LEC3), Endothelin-1 Receptor (EDNRA) and C-X-C Chemokine Receptor 4 (CXCR-4). The invention also provides methods of inhibiting and promoting GPCR-dependent angiogenesis in vertebrates, particular mammals, including humans, for the treatment of angiogenesis-related diseases. The invention also provides methods of identifying compounds that promote or inhibit angiogenesis through their interaction with LEC3, EDNRA and/or CXCR-4. The invention further provides methods of modulating angiogenesis through the modulation of these GPCRs and VEGF.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07750916A EP1996619A4 (en) | 2006-02-14 | 2007-02-14 | Gpcrs as angiogenesis targets |
JP2008555380A JP2009526861A (en) | 2006-02-14 | 2007-02-14 | GPCR as an angiogenic target |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77299106P | 2006-02-14 | 2006-02-14 | |
US60/772,991 | 2006-02-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007095353A2 WO2007095353A2 (en) | 2007-08-23 |
WO2007095353A3 true WO2007095353A3 (en) | 2009-04-16 |
Family
ID=38372149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/004114 WO2007095353A2 (en) | 2006-02-14 | 2007-02-14 | Gpcrs as angiogenesis targets |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1996619A4 (en) |
JP (1) | JP2009526861A (en) |
WO (1) | WO2007095353A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107073078B (en) * | 2014-09-26 | 2021-07-06 | 赫利世弥斯株式会社 | Composition for preventing or treating peripheral arterial disease using hepatocyte growth factor and stromal cell derived factor 1 alpha |
FR3077574B1 (en) * | 2018-02-07 | 2022-04-01 | Commissariat Energie Atomique | ANTIBODIES DIRECTED AGAINST ENDOTHELIN RECEPTOR SUBTYPE A AND THEIR USES. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759804A (en) * | 1992-11-17 | 1998-06-02 | Icos Corporation | Isolated nucleic acid encoding seven transmembrane receptors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0854918A1 (en) * | 1996-01-30 | 1998-07-29 | The National Institutes of Health | Cells expressing both human cd4 and cxcr4 |
US6479256B1 (en) * | 1998-03-04 | 2002-11-12 | Icos Corporation | Lectomedin materials and methods |
US6946445B1 (en) * | 1998-03-13 | 2005-09-20 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
US20020107196A1 (en) * | 1998-07-21 | 2002-08-08 | Smithkline Beecham Corporation | Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha |
JP2004531249A (en) * | 2001-02-14 | 2004-10-14 | プロテイン デザイン ラブス インコーポレイティド | Method for diagnosing angiogenesis, composition, and method for screening angiogenesis modulator |
US20040009171A1 (en) * | 2001-10-18 | 2004-01-15 | Genentech, Inc. | Methods for the treatment of carcinoma |
-
2007
- 2007-02-14 WO PCT/US2007/004114 patent/WO2007095353A2/en active Application Filing
- 2007-02-14 EP EP07750916A patent/EP1996619A4/en not_active Withdrawn
- 2007-02-14 JP JP2008555380A patent/JP2009526861A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759804A (en) * | 1992-11-17 | 1998-06-02 | Icos Corporation | Isolated nucleic acid encoding seven transmembrane receptors |
Non-Patent Citations (1)
Title |
---|
See also references of EP1996619A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1996619A2 (en) | 2008-12-03 |
EP1996619A4 (en) | 2009-11-18 |
WO2007095353A2 (en) | 2007-08-23 |
JP2009526861A (en) | 2009-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000171A1 (en) | Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression. | |
EA201000319A1 (en) | DERIVATIVES OF AZACYCLILYZYOHINOLINONE AND ISOINDOLINONE AS ANTAGONISTS OF HISTAMINE RECEPTORS OF SUBTIP 3 | |
EA201100306A1 (en) | CYCLOGEXILAMIDE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF CRF-1 RECEPTOR | |
CL2007003266A1 (en) | COMPOUNDS DERIVED FROM PROGESTERONA, ANTAGONISTS OF THE PROGESTERONE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF ENDOMETRIOSIS, MYOMAS OR TUMORS DEPENDENT ON HORMONES. | |
WO2010016766A3 (en) | Antibodies recognizing endogenous human lgr5 and/or lgr6 | |
ATE496051T1 (en) | PYRAZOLOTETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | |
BRPI0605921A2 (en) | organic compounds | |
WO2008064054A3 (en) | Compounds which modulate the cb2 receptor | |
WO2006009734A8 (en) | Gonadotropin releasing hormone receptor antagonists | |
MY155621A (en) | Axl antibodies | |
WO2007114926A3 (en) | Kinase antagonists | |
CY1113734T1 (en) | CHEMICAL COMPOUNDS | |
EA200901099A1 (en) | CONNECTIONS AND METHODS FOR MODULATING RECEPTORS CONNECTED WITH G-PROTEIN | |
UY32225A (en) | CICLOALCANO ANTAGONISTS [B] AZAINDOL OF PROSTAGLANDIN D2 RECEPTORS | |
FR2913358B1 (en) | DEVICE FOR IGNITING AN ALUMINOTHERMAL COMPOSITION, HOLLOWING THE INCORPORATING DEVICE AND ASSOCIATED METHODS. | |
WO2006097536A3 (en) | Dimeric peptide agonists of the glp-1 receptor | |
CL2011000976A1 (en) | Compounds derived from isonicotinamide and carboxamide, orexin receptor antagonists; pharmaceutical composition that includes them; and its use for the prevention of a sleep disorder. | |
ATE481405T1 (en) | THIAZOLPYRAZOLOPYRIMIDINES AS ANTAGONISTS OF THE CRF1 RECEPTOR | |
NO20084458L (en) | IL-8 receptor antagonists | |
EA201000316A1 (en) | IZOHINOLINIL AND IZINODOLINIL DERIVATIVES AS ANTAGONISTS OF HISTAMINE RECEPTORS 3 SUBTYPES | |
ATE458740T1 (en) | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | |
ATE496916T1 (en) | QUINICLIDINE DERIVATIVES OF (HETERO)ARYLCYCLOHEPTANCARBOXIC ACIDS AS ANTAGONISTS ON THE MUSCARIN RECEPTOR | |
WO2010116282A8 (en) | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses | |
PL1987357T3 (en) | Polypeptides recognized by anti-trichinella antibodies, and uses thereof | |
WO2009089234A3 (en) | Substituted dibenzhydrylpiperazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2008555380 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007750916 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07750916 Country of ref document: EP Kind code of ref document: A2 |